Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.

New TAVR research explores adverse outcomes, disease progression in patients with asymptomatic severe AS
Two separate studies at ACC.25 explored data from the EARLY TAVR trial. One analysis included stroke findings that surprised researchers.
Dapagliflozin improves outcomes for elderly TAVR patients with heart failure
The positive data were presented as part of a late-breaking clinical trial at ACC.25 in Chicago. One cardiologist on stage for the presentation said these findings will impact the way he manages certain TAVR patients.
American Heart Association program leads to substantial improvements in stroke care
Cardiologist Gregg Fonarow, MD, reviewed decades of data and discussed the long-term impact of the AHA's Get With The Guidelines-Stroke program.
Bringing state-of-the-art healthcare to Florida heart patients
Naples Comprehensive Health is building up what it hopes will be a nationally recognized cardiology program. Robert Cubeddu, MD, and Dee Dee Wang, MD, spoke with Cardiovascular Business about the journey so far.
Society of Interventional Radiology seeks to bolster research funding for the specialty
During their annual meeting being held this week in Nashville, the society announced the launch of the SIR Foundation Endowment.

A late-breaking science presentation at the annual TCT interventional cardiology meeting.

Late-breaking clinical trials at TCT 2023

Here is a list of all the late-breaking clinical trials being presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2023 annual meeting Oct. 23-26, 2023, in San Francisco.

Number of AI products in healthcare set for fivefold expansion by 2035

A study projects AI funding will continue to increase, resulting in a massive number of new products during the next decade.

ACC President Hadley Wilson, MD, explained the impact of 4 key ESC 2023 IVUS and OCT intravascular imaging trials and wht thaey will l;ikely influence PCI guidelines. #ESC ESC23 #ESC2023 #ACC

Intravascular imaging for PCI gets a big boost from recent studies

ACC President Hadley Wilson, MD, explains the big impact four late-breaking studies on intravascular imaging may have on revising PCI guidelines.

Technology that creates interactive holograms of the heart cleared by FDA

SentiAR's CommandEP interface facilitates 3D models of the heart, made possible through augmented reality.

The central figure from the study "Predictors and Variation in Cardiac Rehabilitation Participation After Transcatheter Aortic Valve Replacement study 2023," showing the wide variation in the percentage of patients who receive post-TAVR rehab among TAVR patients in Michigan.

Less than one-third of TAVR patients enter cardiac rehab

Only about 30% of patients who underwent TAVR in Michigan participated in cardiac rehabilitation within 90 days after discharge.

Direct acyclic graph representing a causal structural model of mediation of the association between obesity in early pregnancy and cardiovascular disease (CVD) risk factors after delivery. E indicates exposure; GDM, gestational diabetes; HDP, hypertensive disorders of pregnancy; M, mediators; O, outcome; PTB, preterm birth; SBP, systolic blood pressure; SGA, small-for-gestational-age birth; and TC, total cholesterol. *Variable included in sensitivity analysis.

Pregnancy complications increase and unmask cardiovascular risks in obese patients in NIH study

New research is providing a broader understanding of how cardiovascular disease risk manifests following pregnancy. Having obesity before and during early pregnancy appears to be a strong indicator of risk for developing future cardiovascular disease and was significantly linked with adverse outcomes during pregnancy.

Specialists at Cleveland Clinic treated a hypertrophic cardiomyopathy patient with a new gene therapy from Tenaya Therapeutics

Cleveland Clinic treats first patient with new gene therapy for hypertrophic cardiomyopathy

Researchers hopes this first-in-class gene therapy, known as TN-201, can restore the patient’s MYBPC3 levels and eventually lead to disease reversal.

Dihydropyridines such as amlodipine have been the topic of some debate in recent months due to fears they lead to significant side effects.

Clinical

New TAVR research explores adverse outcomes, disease progression in patients with asymptomatic severe AS

Dapagliflozin improves outcomes for elderly TAVR patients with heart failure

American Heart Association program leads to substantial improvements in stroke care

Bringing state-of-the-art healthcare to Florida heart patients

Society of Interventional Radiology seeks to bolster research funding for the specialty